FGFR2 and pancreatic neoplasm: Dovitinib treatment in combination with FGFR shRNA transfection achieved significant anti‐tumour effects in pancreatic cancer, especially in FGFR2 IIIb overexpressing pancreatic cancer cells.92 Furthermore, FGFR2 IIIc was highly expressed in PDAC tissues, which is associated with liver metastasis in PDAC patients.